[1] Nagata Y, Inoue H, Yamada K, et al. Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients[J]. Immunology, 2004, 111(2): 223-229.
[2] Willoughby CE, Baker K, Kaye SB, et al. Epstein‐Barr virus (types 1 and 2) in the tear film in Sjogren's syndrome and HIV infection[J]. J Med Virol, 2002, 68(3): 378-383.
[3] Ramos-Casals M, Garcìa-Carrasco M, Cervera R, et al. Hepatitis C virus infection mimicking primary Sjogren syndrome. A clinical and immunologic description of 35 cases[J]. Medicine(Baltimore), 2001, 80(1): 1-8.
[4] Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al. Sjogren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases[J]. Medicine(Baltimore), 2005, 84(2): 81-89.
[5] Doffoel-Hantz V, Loustaud-Ratti V, Ramos-Casals M, et al. Evolution of Sjogren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin[J]. Rev Med Interne, 2005, 26(2): 88-94.
[6] Moser KL,Harley JB. Genomics and viruses in Sjogren's syndrome[M]// Fox RI, Fox CM. Sjogren's syndrome: practial guidelines to diagnosis and therapy. New York:Springer, 2011: 93-110.
[7] Mariette X, Gottenberg JE. Pathogenesis of Sjogren's syndrome and therapeutic consequences [J]. Curr Opin Rheumatol, 2010, 22(5):471-477.
[8] Taiym S, Haghighat N, Al-Hashimi I. A comparison of the hormone levels in patients with Sjogren's syndrome and healthy controls[J]. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endod, 2004, 97(5): 579-583.
[9] Forsblad-d'Elia H, Carlsten H, Labrie F, et al. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations[J]. J Clin Endocrinol Metab, 2009, 94(6): 2044-2051.
[10] Nikolov NP, Illei GG. Pathogenesis of Sjogren's syndrome [J]. Curr Opin Rheumatol, 2009, 21(5):465-470.
[11] Lin X, Song JX, Shaw PC, et al. An autoimmunized mouse model recapitulates key features in the pathogenesis of Sjogren's syndrome[J]. Int Immunol, 2011,23(10):613-624.
[12] Dawson LJ, Fox PC, Smith PM. Sjogren's syndrome-the non-apoptotic model of glandular hypofunction[J]. Rheumatol(Oxford), 2006, 45(7):792-798.
[13] 俞创奇,邱蔚六,胡北平,等. 舍格伦综合征的发病机理和病因研究现状[J].上海口腔医学, 1999, 8(3):184-186.
[14] Fox RI, Saito I. Sjogren's syndrome[M]//Michael Hertl. Autoimmune disease of the skin: pathogenesis, diagnosis, management. 2nd ed. Vienna: Springer, 2005: 261-289.
[15] Larché MJ. A short review of the pathogenesis of Sjogren's syndrome[J]. Autoimmun Rev, 2006, 5: 132-135.
[16] Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjogren's syndrome[J]. Crit Rev Oral Biol Med,1996, 7(2):144-158.
[17] Hayashi T, Shimoyama N, Mizuno T. Destruction of salivary and lacrimal glands by Th1-polarized reaction in a model of secondary Sjogren's syndrome in lupus-prone female NZB × NZWF(1) mice[J]. Inflammation, 2012, 35(2):638-646.
[18] Wang SS, Purdue MP, Cerhan JR, et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk[J]. PLoS One, 2009, 4(4): e5360.
[19] Mavragani CP, Crow MK, et al. Activation of the type I interferon pathway in primary Sjogren's syndrome[J]. J Autoimmun, 2010, 35(3): 225-231.
[20] Zheng LY, Zhang ZY, Yu L, et al. Association between IFN-α and primary Sjogren's syndrome[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2009, 107(1): e12-e18.
[21] Pérez P, Anaya JM, Agullera S, et al. Gene expression and chromosomal location for susceptibility to Sjogren's syndrome[J]. J Autoimmun, 2009,33(2):99-108.
[22] Soyfoo MS, Steinfeld S, Delporte C. Usefulness of mouse models to study the pathogenesis of Sjogren's syndrome[J]. Oral diseases, 2007, 13(4): 366-375.
[23] Yin H, Zhao M, Wu X, et al. Hypomethylation and overexpression of CD70 (TNFSF7) in CD4+ T cells of patients with primary Sjogren's syndrome[J]. J Dermatol Sci, 2010, 59(3): 198-203.
[24] Killedar SJ, Eckenrode SE, McIndoe RA, et al. Early pathogenic events associated with Sjogren's syndrome (SjS)-like disease of the NOD mouse using microarray analysis[J]. Lab Invest, 2006, 86(12): 1243-1260.
[25] Ohlsson M, Szodoray P, Loro LL, et al. CD40, CD154, Bax and Bcl-2 expression in Sjogren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases[J]. Scand J Immunol, 2002, 56(6): 561-571. |